Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 3;10:531–551. doi: 10.2147/JHC.S400472

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Dai et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effect of ST6GALNAC4 knockdown on hepatoma cells. (A) Expression of PD-L1 and B7-H3 mRNA in hepatoma cells after ST6GALNAC4 knockdown. (B and C) Flow cytometric and Western blot analyses of PD-L1 and B7-H3 expression in hepatoma cells after ST6GALNAC4 knockdown. (D) CCK-8 analysis of the effect of ST6GALNAC4 knockdown on the proliferative capacity of hepatoma cells. (E and F) Effect of ST6GALNAC4 knockdown on the clone formation ability and cell cycle of hepatoma cells. (G and H) ST6GALNAC4 knockdown inhibited the migration and invasion ability of hepatoma cells. ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001.

Abbreviation: PD-L1, programmed cell death-1 ligand 1.